Top

Published in:

Open Access 01-12-2024 | Review

Preclinical evidence and possible mechanisms of cardioprotective effects of resveratrol in diabetic cardiomyopathy: a systematic review and meta-analysis

Authors: Xiaodan Yan, Youjia Hu, Shuyuan Zhao, Qian Zhou, Qiu Chen

Published in: Diabetology & Metabolic Syndrome | Issue 1/2024

Abstract

Introduction

Diabetic cardiomyopathy (DCM) is a significant complication of diabetes, characterized primarily by the development of heart failure in individuals with diabetes. Numerous animal studies have indicated that resveratrol enhances cardiac function in diabetic cardiomyopathy; however, its reliability and underlying mechanism remain unclear. This study aims to assess the cardioprotective effects of resveratrol on DCM and explore its potential mechanism.

Methods

We searched PubMed, EMBASE, WOS, Cochrane Library, CNKI, CBM, Chinese VIP, and Wan Fang Database until March 31st, 2024, without language restrictions. Continuous outcome measures were analyzed using weighted mean difference or standardized mean difference, and heterogeneity was assessed with I². The risk of bias in animal experiments was evaluated using the SYRCLE tool, and evidence reliability was determined with the GRADE tool. All data were analyzed using Review Manager 5.4.1 and Stata 17. This study has been registered on the PROSPERO (CRD42024523944).

Results

A total of 18 studies meeting the criteria were identified. The analysis revealed that the resveratrol intervention group exhibited significant improvements in LVEF (WMD = 17.88), LVFS (WMD = 8.77), HW/BW (SMD=-2.92), SOD (SMD = 4.53), and MDA (SMD=-5.07) compared to the control group. The GRADE grading assessment indicated moderate certainty for LVEF, HW/BW, and MDA, while certainty for other factors was considered low.

Conclusion

Our research suggests that resveratrol may protect cardiac function in DCM through anti-inflammatory and anti-oxidative stress effects. However, these findings are based on preclinical data, and further extensive trials are needed to confirm their effectiveness and safety before clinical application.

Available only for authorised users

Dillmann WH. Diabetic Cardiomyopathy. Circ Res. 2019;124(8):1160–2. https://doi.org/10.1161/circresaha.118.314665.CrossRefPubMedPubMedCentral

Seferović PM, Paulus WJ, Rosano G, Polovina M, Petrie MC, Jhund PS, et al. Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases. Eur J Heart Fail. 2024. https://doi.org/10.1002/ejhf.3347.CrossRefPubMed

Glovaci D, Fan W, Wong ND. Epidemiology of diabetes Mellitus and Cardiovascular Disease. Curr Cardiol Rep. 2019;21(4):21. https://doi.org/10.1007/s11886-019-1107-y.CrossRefPubMed

Dauriz M, Mantovani A, Bonapace S, Verlato G, Zoppini G, Bonora E, et al. Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a Meta-analysis. Diabetes Care. 2017;40(11):1597–605. https://doi.org/10.2337/dc17-0697.CrossRefPubMed

Dauriz M, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, et al. Prognostic impact of diabetes and prediabetes on survival outcomes in patients with Chronic Heart failure: a post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza Nella Insufficienza Cardiaca-Heart failure) trial. J Am Heart Association. 2017;6(7). https://doi.org/10.1161/jaha.116.005156.

Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–140. https://doi.org/10.1093/eurheartj/ehad192.CrossRefPubMed

Jia G, Hill MA, Sowers JR. Diabetic Cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624–38. https://doi.org/10.1161/circresaha.117.311586.CrossRefPubMedPubMedCentral

Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Reviews Cardiol. 2020;17(9):585–607. https://doi.org/10.1038/s41569-020-0339-2.CrossRef

Murtaza G, Virk HUH, Khalid M, Lavie CJ, Ventura H, Mukherjee D, et al. Diabetic cardiomyopathy - A comprehensive updated review. Prog Cardiovasc Dis. 2019;62(4):315–26. https://doi.org/10.1016/j.pcad.2019.03.003.CrossRefPubMed

10.

Xu G, Zhao X, Fu J, Wang X. Resveratrol increase myocardial Nrf2 expression in type 2 diabetic rats and alleviate myocardial ischemia/reperfusion injury (MIRI). Annals Palliat Med. 2019;8(5):565–75. https://doi.org/10.21037/apm.2019.11.25.CrossRef

11.

Sung MM, Hamza SM, Dyck JR. Myocardial metabolism in diabetic cardiomyopathy: potential therapeutic targets. Antioxid Redox Signal. 2015;22(17):1606–30. https://doi.org/10.1089/ars.2015.6305.CrossRefPubMed

12.

Kroon PA, Iyer A, Chunduri P, Chan V, Brown L. The Cardiovascular Nutrapharmacology of Resveratrol: Pharmacokinetics, Molecular mechanisms and therapeutic potential. Curr Med Chem. 2010;17(23):2442–55. https://doi.org/10.2174/092986710791556032.CrossRefPubMed

13.

Abdelhaleem IA, Brakat AM, Adayel HM, Asla MM, Rizk MA, Aboalfetoh AY. The effects of resveratrol on glycemic control and cardiometabolic parameters in patients with T2DM: a systematic review and meta-analysis. Med Clin. 2022;158(12):576–85. https://doi.org/10.1016/j.medcli.2021.06.028.CrossRef

14.

Delpino FM, Figueiredo LM. Resveratrol supplementation and type 2 diabetes: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2022;62(16):4465–80. https://doi.org/10.1080/10408398.2021.1875980.CrossRefPubMed

15.

Ahmad I, Hoda M. Molecular mechanisms of action of resveratrol in modulation of diabetic and non-diabetic cardiomyopathy. Pharmacol Res. 2020;161:12. https://doi.org/10.1016/j.phrs.2020.105112.CrossRef

16.

Wang G, Song X, Zhao L, Li Z, Liu B. Resveratrol prevents Diabetic Cardiomyopathy by increasing Nrf2 expression and transcriptional activity. Biomed Res Int. 2018;2018:2150218. https://doi.org/10.1155/2018/2150218.CrossRefPubMedPubMedCentral

17.

Fang WJ, Li XM, Zhou XK, Xiong Y. Resveratrol improves diabetic cardiomyopathy by preventing asymmetric dimethylarginine-caused peroxisome proliferator-activated receptor-γ coactivator-1α acetylation. Eur J Pharmacol. 2022;936:175342. https://doi.org/10.1016/j.ejphar.2022.175342.CrossRefPubMed

18.

Diao J, Wei J, Yan R, Fan G, Lin L, Chen M. Effects of resveratrol on regulation on UCP2 and cardiac function in diabetic rats. J Physiol Biochem. 2019;75(1):39–51. https://doi.org/10.1007/s13105-018-0648-7.CrossRefPubMed

19.

Fang WJ, Wang CJ, He Y, Zhou YL, Peng XD, Liu SK. Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1α deacetylation. Acta Pharmacol Sin. 2018;39(1):59–73. https://doi.org/10.1038/aps.2017.50.CrossRefPubMed

20.

Higgins JP, Green SJW-B. Cochrane Handbook for Systematic Reviews of Interventions. 2008.

21.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res ed). 2021;372:n71. https://doi.org/10.1136/bmj.n71.CrossRef

22.

Cordis GA, Das DK, Riedel W. High-performance liquid chromatographic peak identification of 2,4-dinitrophenylhydrazine derivatives of lipid peroxidation aldehydes by photodiode array detection. J Chromatogr A. 1998;798(1–2):117–23. https://doi.org/10.1016/s0021-9673(97)01161-8.CrossRefPubMed

23.

Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43. https://doi.org/10.1186/1471-2288-14-43.CrossRefPubMedPubMedCentral

24.

GH G, AD O, Y F-Y GEVRK, P A-C et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. 2008;336(7650):924–6. https://doi.org/10.1136/bmj.39489.470347.AD

25.

Canbolat İP, Çavuşoğlu T, Yiğittürk G, Ateş U, Erbaş O. The protective role of Resveratrol on Diabetic Cardiomyopathy in Streptozocin Induced Diabetic rats. E J Cardiovasc Med. 2020;7(2):84–8. https://doi.org/10.32596/ejcm.galenos.2019.00023.CrossRef

26.

Ma S, Feng J, Zhang R, Chen JW, Han D, Li X, et al. SIRT1 activation by Resveratrol alleviates Cardiac Dysfunction via mitochondrial regulation in Diabetic Cardiomyopathy mice. Oxidative Med Cell Longev. 2017;2017:15. https://doi.org/10.1155/2017/4602715.CrossRef

27.

Mohammadshahi M, Haidari F, Soufi FG. Chronic resveratrol administration improves diabetic cardiomyopathy in part by reducing oxidative stress. Cardiol J. 2014;21(1):39–46. https://doi.org/10.5603/CJ.a2013.0051.CrossRefPubMed

28.

ShamsEldeen AM, Ashour H, Shoukry HS, Fadel M, Kamar SS, Aabdelbaset M, et al. Combined treatment with systemic resveratrol and resveratrol preconditioned mesenchymal stem cells, maximizes antifibrotic action in diabetic cardiomyopathy. J Cell Physiol. 2019;234(7):10942–63. https://doi.org/10.1002/jcp.27947.CrossRefPubMed

29.

Song X, Huang G, Han W, Zhao Y, Dong P. Protective effect of resveratrol in combination with ursolic acid against diabetic cardiomyopathy via improving myocardial function and attenuation of inflammation and oxidative stress. Acta Pol Pharm - Drug Res. 2020;77(4):601–7. https://doi.org/10.32383/appdr/123535.CrossRef

30.

Wang G, Song XJ, Zhao L, Li ZB, Liu B. Resveratrol prevents Diabetic Cardiomyopathy by increasing Nrf2 expression and transcriptional activity. Biomed Res Int. 2018;2018:13. https://doi.org/10.1155/2018/2150218.CrossRef

31.

Wu ZY, Huang AQ, Yan JY, Liu B, Liu QC, Zhang JW, et al. Resveratrol ameliorates Cardiac Dysfunction by inhibiting apoptosis via the PI3K/Akt/FoxO3a pathway in a rat model of Diabetic Cardiomyopathy. J Cardiovasc Pharmacol. 2017;70(3):184–93. https://doi.org/10.1097/fjc.0000000000000504.CrossRefPubMed

32.

Yan R, Shan H, Lin L, Zhang M, Diao JY, Li Q, et al. Chronic resveratrol treatment improves cardiac function in a rat model of diabetic cardiomyopathy via attenuation of mitochondrial injury and myocardial apoptosis. Int J Clin Exp Med. 2016;9(11):21156–67.

33.

Hongliang D. Protective effects of resveratrol on cardiomyopathy in type 2 diabetic rats. Mod J Integr Traditional Chin Western Med. 2013;22(14):1498–501. https://doi.org/10.3969/j.issn.1008-8849.2013.14.006.CrossRef

34.

Jadan. HDHJYH. Resveratrol promotes autophagy and inhibits type 2 diabetic cardiomyopathy by upregulating SIRT1. Chin J New Drugs Clin Remedies. 2017;26(24):2970–7.

35.

Qing HA. The mechanism of resveratrol based on PI3K/Akt/FoxO3a pathway to protect cardiac function in rats with diabetic cardiomyopathy. Southern Medical University; 2017.

36.

Ke LG, Weijin F. Effect of resveratrol on cardiac dysfunction and acid sphingomyelinase ceramide pathway in diabetic rats. Chin J Pathophysiology. 2018;34(07):1206–13. https://doi.org/10.3969/j.issn.1000-4718.2018.07.009.CrossRef

37.

Zhimin. Z XT, Yanhai. Z LJ, Baimei X. Protective effect of resveratrol on myocardial injury in diabetic mice and its mechanism. Progress Mod Biomed. 2018;18(9):1669–73. https://doi.org/10.13241/j.cnki.pmb.2018.09.014.CrossRef

38.

Wenqiu W, Peng. W QL, Feng. H, Wang. Y-l, Jianjuan. K. Effect of resveratrol on cardiomyocyte ferroptosis in mice with diabetic cardiomyopathy. Chin J Anesthesiology. 2023;43(7):858–62. https://doi.org/10.3760/cma.j.cn131073.20230419.00719.CrossRef

39.

Hui BWRL, Yongqing H. Resveratrol regulates mitophagy in diabetic myocardium through AMPK-P53 pathway. J Lanzhou Univ (Medical Sciences). 2020;46(1):67–716. https://doi.org/10.13885/j.issn.1000-2812.2020.01.013.CrossRef

40.

Guoxiang W, Xiaoli. C, Shunxiang. L ML, Yanqing W. Protective effect of resveratrol on cardiac function in rats with diabetic cardiomyopathy. Chin J Clin Pharmacol. 2019;35(19):2332–5. https://doi.org/10.13699/j.cnki.1001-6821.2019.19.038.CrossRef

41.

Wang Y, Zhou Y, Zhang Y, Ren Q, Wang Y, Su H. Female is Associated with Left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Metabolic Syndrome Obesity: Targets Therapy. 2023;16:2355–64. https://doi.org/10.2147/dmso.S421761.CrossRefPubMed

42.

Toedebusch R, Belenchia A, Pulakat L. Diabetic Cardiomyopathy: impact of Biological Sex on Disease Development and Molecular signatures. Front Physiol. 2018;9:453. https://doi.org/10.3389/fphys.2018.00453.CrossRefPubMedPubMedCentral

43.

Ren J, Ceylan-Isik AF. Diabetic cardiomyopathy: do women differ from men? Endocrine. 2004;25(2):73–83. https://doi.org/10.1385/endo:25:2.CrossRefPubMed

44.

Heather LC, Hafstad AD, Halade GV, Harmancey R, Mellor KM, Mishra PK, et al. Guidelines on models of diabetic heart disease. Am J Physiol Heart Circ Physiol. 2022;323(1):H176–200. https://doi.org/10.1152/ajpheart.00058.2022.CrossRefPubMedPubMedCentral

45.

Calligaris SD, Lecanda M, Solis F, Ezquer M, Gutiérrez J, Brandan E, et al. Mice long-term high-fat diet feeding recapitulates human cardiovascular alterations: an animal model to study the early phases of diabetic cardiomyopathy. PLoS ONE. 2013;8(4):e60931. https://doi.org/10.1371/journal.pone.0060931.CrossRefPubMedPubMedCentral

46.

Verboven M, Deluyker D, Ferferieva V, Lambrichts I, Hansen D, Eijnde BO, et al. Western diet given to healthy rats mimics the human phenotype of diabetic cardiomyopathy. J Nutr Biochem. 2018;61:140–6. https://doi.org/10.1016/j.jnutbio.2018.08.002.CrossRefPubMed

47.

Richter C, Hinkel R. Research(‘s) Sweet hearts: experimental Biomedical models of Diabetic Cardiomyopathy. Front Cardiovasc Med. 2021;8:703355. https://doi.org/10.3389/fcvm.2021.703355.CrossRefPubMedPubMedCentral

48.

Meindl C, Hochadel M, Frankenstein L, Bruder O, Pauschinger M, Hambrecht R, et al. The role of diabetes in cardiomyopathies of different etiologies-characteristics and 1-year follow-up results of the EVITA-HF registry. PLoS ONE. 2020;15(6):e0234260. https://doi.org/10.1371/journal.pone.0234260.CrossRefPubMedPubMedCentral

49.

Julián MT, Alonso N, Lupón J, Gavidia-Bovadilla G, Ferrer E, de Antonio M, et al. Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline. Cardiovasc Diabetol. 2020;19(1):38. https://doi.org/10.1186/s12933-020-01011-w.CrossRefPubMedPubMedCentral

50.

Huang D-D, Shi G, Jiang Y, Yao C, Zhu C. A review on the potential of Resveratrol in prevention and therapy of diabetes and diabetic complications. Biomed Pharmacother. 2020;125. https://doi.org/10.1016/j.biopha.2019.109767.

51.

Song Y-J, Zhong C-B, Wu W. Resveratrol and Diabetic Cardiomyopathy: focusing on the Protective Signaling mechanisms. Oxidative Med Cell Longev. 2020;2020:1–19. https://doi.org/10.1155/2020/7051845.CrossRef

52.

Ye H, Zhang Y, Yun Q, Du R, Li L, Li Y, et al. [Resveratrol alleviates hyperglycemia-induced cardiomyocyte hypertrophy by maintaining mitochondrial homeostasis via enhancing SIRT1 expression]. Nan Fang Yi Ke da xue xue bao = Journal. South Med Univ. 2024;44(1):45–51. https://doi.org/10.12122/j.issn.1673-4254.2024.01.06.CrossRef

53.

Fang W-j, Wang C-j, He Y, Zhou Y-l, Peng X-d. Liu S-k. Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1α deacetylation. Acta Pharmacol Sin. 2017;39(1):59–73. https://doi.org/10.1038/aps.2017.50.CrossRefPubMedPubMedCentral

54.

Liu G, Yan D, Yang L, Sun Y, Zhan L, Lu L, et al. The effect of mir-471-3p on macrophage polarization in the development of diabetic cardiomyopathy. Life Sci. 2021;268:118989. https://doi.org/10.1016/j.lfs.2020.118989.CrossRefPubMed

55.

Bagul P, Katare P, Bugga P, Dinda A, Banerjee SK. SIRT-3 modulation by Resveratrol Improves Mitochondrial Oxidative Phosphorylation in Diabetic Heart through Deacetylation of TFAM. Cells. 2018;7(12). https://doi.org/10.3390/cells7120235.

56.

Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2017;19(2):121–35. https://doi.org/10.1038/nrm.2017.95.CrossRefPubMedPubMedCentral

57.

Li J, Feng Z, Lu B, Fang X, Huang D, Wang B. Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation. Biochem Biophys Rep. 2023;34. https://doi.org/10.1016/j.bbrep.2023.101444.

58.

Yang L, Gao Z, Zhao H, Zhang Z, Song G. Resveratrol Delays Diabetic Cardiomyopathy Fibrosis by Regulating Mitochondrial Autophagy. Alternative therapies in health and medicine. 2024.

59.

Xu K, Liu X-f, Ke Z-q, Yao Q, Guo S, Liu C. Resveratrol modulates apoptosis and Autophagy Induced by High glucose and Palmitate in Cardiac cells. Cell Physiol Biochem. 2018;46(5):2031–40. https://doi.org/10.1159/000489442.CrossRefPubMed

60.

He F, Ru X, Wen T. NRF2, a transcription factor for stress response and Beyond. Int J Mol Sci. 2020;21(13). https://doi.org/10.3390/ijms21134777.

61.

Zhu N, Huang B, Zhu L. Bibliometric analysis of the inflammation in diabetic cardiomyopathy. Front Cardiovasc Med. 2022;9. https://doi.org/10.3389/fcvm.2022.1006213.

62.

Lin H, Ogawa K, Imanaga I, Tribulova N. Alterations of connexin 43 in the diabetic rat heart. Adv Cardiol. 2006;42:243–54. https://doi.org/10.1159/000092573.CrossRefPubMed

63.

Wang G-Y, Bi Y-G, Liu X-D, Han J-F, Wei M, Zhang Q-Y. Upregulation of connexin 43 and apoptosis-associated protein expression by high glucose in H9c2 cells was improved by resveratrol via the autophagy signaling pathway. Mol Med Rep. 2017;16(3):3262–8. https://doi.org/10.3892/mmr.2017.6953.CrossRefPubMedPubMedCentral

64.

Wu H, Sheng Z-Q, Xie J, Li R, Chen L, Li G-N, et al. Reduced HMGB 1-Mediated pathway and oxidative stress in resveratrol-treated Diabetic mice: a possible mechanism of Cardioprotection of Resveratrol in Diabetes Mellitus. Oxidative Med Cell Longev. 2016;2016:1–10. https://doi.org/10.1155/2016/9836860.CrossRef

65.

He DW, Liu DZ, Luo XZ, Chen CB, Lu CH, Na N, et al. HMGB1-RAGE axis contributes to myocardial ischemia/reperfusion injury via regulation of cardiomyocyte autophagy and apoptosis in diabetic mice. Biol Chem. 2024;405(3):167–76. https://doi.org/10.1515/hsz-2023-0134.CrossRefPubMed

66.

Wu H, Li G-N, Xie J, Li R, Chen Q-H, Chen J-Z, et al. Resveratrol ameliorates myocardial fibrosis by inhibiting ROS/ERK/TGF-β/periostin pathway in STZ-induced diabetic mice. BMC Cardiovasc Disord. 2016;16(1). https://doi.org/10.1186/s12872-015-0169-z.

67.

Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Reviews Endocrinol. 2015;12(3):144–53. https://doi.org/10.1038/nrendo.2015.216.CrossRef

68.

Carolo dos Santos K, Pereira Braga C, Octavio Barbanera P, Rodrigues Ferreira Seiva F, Fernandes Junior A, Fernandes AA. Cardiac energy metabolism and oxidative stress biomarkers in diabetic rat treated with resveratrol. PLoS One. 2014;22;9(7):e102775. https://doi.org/10.1371/journal.pone.0102775.

Title: Preclinical evidence and possible mechanisms of cardioprotective effects of resveratrol in diabetic cardiomyopathy: a systematic review and meta-analysis
Authors: Xiaodan Yan
Youjia Hu
Shuyuan Zhao
Qian Zhou
Qiu Chen
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: Diabetology & Metabolic Syndrome / Issue 1/2024
Electronic ISSN: 1758-5996
DOI: https://doi.org/10.1186/s13098-024-01512-8

The prognostic value of triglyceride-glucose index to adverse renal outcomes in patients with type 2 diabetes mellitus: results from the cohort study of ACCORD

Open Access
Type 2 Diabetes
Research

The U-shape relationship between insulin resistance-related indexes and chronic kidney disease: a retrospective cohort study from National Health and Nutrition Examination Survey 2007–2016

Open Access
Chronic Kidney Disease
Research

Enhancing insulin sensitivity in type 2 diabetes mellitus using apelin-loaded small extracellular vesicles from Wharton’s jelly-derived mesenchymal stem cells: a novel therapeutic approach

Open Access
Insulins
Research

Association of maternal exposure to endocrine disruptor chemicals with cardio-metabolic risk factors in children during childhood: a systematic review and meta-analysis of cohort studies

Open Access
Review

Relationship between gout, hyperuricemia, and obesity—does central obesity play a significant role?—a study based on the NHANES database

Open Access
Gout
Research

Causal relationships between GLP1 receptor agonists, blood lipids, and heart failure: a drug-target mendelian randomization and mediation analysis

Open Access
Heart Failure
Research

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content